https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-05-03 / Hum Vaccin Immunother 2023 May;:2198467
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-05-03 / Hum Vaccin Immunother 2023 May;:21984672023-05-03 00:00:002023-05-03 00:00:00Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-03-07 / Cancer Immunol Immunother 2023 Mar;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-03-07 / Cancer Immunol Immunother 2023 Mar;2023-03-07 00:00:002023-03-07 00:00:00A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-01-09 / Curr Opin Oncol 2023 Mar;35(2):87-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-01-09 / Curr Opin Oncol 2023 Mar;35(2):87-932023-01-09 00:00:002023-01-09 00:00:00Current „state of the art“ on dendritic cell-based cancer vaccines in melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-07-07 / Cancer Res Commun 2022 Jul;2(7):602-615
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-07-07 / Cancer Res Commun 2022 Jul;2(7):602-6152022-07-07 00:00:002022-07-07 00:00:00Avian Paramyxovirus 4 Antitumor Activity Leads to Complete Remissions and Long-term Protective Memory in Preclinical Melanoma and Colon Carcinoma Models
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-08-09 / J Clin Oncol 39, 2021 (suppl 15; abstr 2618)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-08-09 / J Clin Oncol 39, 2021 (suppl 15; abstr 2618)2021-08-09 09:43:272021-08-09 09:43:27Long-term follow up of patients with mesothelioma treated with dendritic cell therapy in three phase I trials.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-08-01 / Melanoma Res 2021 Aug;31(4):378-388
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-08-01 / Melanoma Res 2021 Aug;31(4):378-3882021-08-01 00:00:002023-01-31 12:55:32Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-07-19 / Sci Rep 2021 Jul;11(1):14661
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-07-19 / Sci Rep 2021 Jul;11(1):146612021-07-19 00:00:002021-07-19 00:00:00Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-06-29 / J Eur Acad Dermatol Venereol 2021 Oct;35(10):1976-1986
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-06-29 / J Eur Acad Dermatol Venereol 2021 Oct;35(10):1976-19862021-06-29 00:00:002021-06-29 00:00:00A Bayesian network meta-analysis of comparison of cancer therapeutic vaccines for melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-05-19 / Vaccines (Basel) 2021 May;9(5)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-05-19 / Vaccines (Basel) 2021 May;9(5)2021-05-19 00:00:002021-05-19 00:00:00Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-05-12 / Cancer Med 2021 Jul;10(13):4302-4311
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-05-12 / Cancer Med 2021 Jul;10(13):4302-43112021-05-12 00:00:002021-08-09 09:14:27Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis
